Mediclinic International Plc

Public consensus   -   Last updated 22/09/21

Contributors

  • 13 FY22 based on
  • 13 FY23 based on
  • 13 FY24 based on
  • 10 FY25 based on
Reporting currency: GBP
Reporting unit: Absolute
FY22
CONSENSUS
22/09/21
FY23
CONSENSUS
22/09/21
FY24
CONSENSUS
22/09/21
FY25
CONSENSUS
22/09/21
Hirslanden (CHF'm) - Adjusted
Revenue
1,817
1,863
1,898
1,925
EBITDA
283
305
316
324
EBITDA margin (%)
15.6
16.4
16.6
16.8
Average FX rate GBP/CHF
1.25
1.26
1.26
1.24
Southern Africa (ZAR'm) - Adjusted
Revenue
17,193
18,461
19,435
20,191
EBITDA
3,169
3,696
3,951
4,167
EBITDA margin (%)
18.4
20.0
20.3
20.6
Average FX rate GBP/ZAR
20.39
20.44
20.69
21.01
Middle East (AED'm) - Adjusted
Revenue
3,946
4,134
4,311
4,488
EBITDA
580
642
697
742
EBITDA margin (%)
14.7
15.5
16.2
16.5
Average FX rate GBP/AED
5.05
5.06
5.04
4.99
Adjusted Group (GBP'm)
Revenue
3,074
3,201
3,303
3,406
EBITDA
494
548
578
605
EBITDA margin (%)
16.1
17.1
17.5
17.7
D&A
(218)
(224)
(227)
(233)
Operating profit
276
324
351
372
Net finance cost
(71)
(69)
(68)
(65)
Share of profit of equity accounted investment
1
6
9
11
Earnings (equity holders)
148
189
213
234
Earnings per share (pence)
20.0
25.5
28.8
31.6
Dividend per share (pence)
3.2
6.9
7.9
8.6
Net Debt
1,902
1,771
1,607
1,453
Net cash generated from operating activities
371
407
446
470
Total Group Capex
220
204
204
211

Disclaimer

Mediclinic International plc (“Mediclinic”) does not endorse or adopt any of the consensus estimates expressed in this report. The report represents the views of analysts from which the consensus estimates are derived. Mediclinic will not provide any commentary on the consensus or answer questions on it. The circulation of the consensus by Mediclinic is not mandatory and Mediclinic may amend its practice on this at any time.